Mdm2 in growth signaling and cancer

Growth Factors

Volumn 23, Issue 3, 2005, Pages 183-192

  Levav Cohen, Yaara ^a   Haupt, Sue ^a   Haupt, Ygal ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Akt; E2F; Mdm2; p53; Steroid receptors; TGF

Indexed keywords

1,3 DIPHENYL 2 PROPEN 1 ONE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; CHALCONE DERIVATIVE; IMIDAZOLINE DERIVATIVE; PROTEIN MDM2; STEROID RECEPTOR; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BIOCHEMISTRY; CANCER CLASSIFICATION; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; CELL GROWTH; CYTOTOXICITY; DEREGULATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE TARGETING; GENETIC ANALYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL SURVIVAL; GROWTH SUBSTANCES; HUMANS; MICE; NEOPLASMS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 32144435931     PISSN: 08977194     EISSN: None     Source Type: Journal    
DOI: 10.1080/08977190500196218     Document Type: Review

References (89)

1. Ashcroft, M and Ludwig, RL and Woods, DB and Copeland, TD and Weber, HO and MacRae, EJ and Vousden, KH. (2002) Phosphorylation of HDM2 by Akt Oncogene, 21, pp. 1955-1962.
2. Bartek, J and Lukas, J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell, 3, pp. 421-429.
3. Blain, SW and Massague, J. (2000) Different sensitivity of the transforming growth factor-beta cell cycle arrest pathway to c-Myc and MDM-2 J Biol Chem, 275, pp. 32066-32070.
4. Bond, GL and Hu, W and Bond, EE and Robins, H and Lutzker, SG and Arva, NC and Bargonetti, J and Bartel, F and Taubert, H and Wuerl, P and (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell, 119, pp. 591-602.
5. Butler, AA and Yakar, S and Gewolb, IH and Karas, M and Okubo, Y and LeRoith, D. (1998) Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology Comp Biochem Physiol B Biochem Mol Biol, 121, pp. 19-26.
6. Chaussepied, M and Ginsberg, D. (2004) Transcriptional regulation of AKT activation by E2F Mol Cell, 16, pp. 831-837.
7. Cordenonsi, M and Dupont, S and Maretto, S and Insinga, A and Imbriano, C and Piccolo, S. (2003) Links between tumor suppressors: P53 is required for TGF-beta gene responses by cooperating with Smads Cell, 113, pp. 301-314.
8. Datta, SR and Brunet, A and Greenberg, ME. (1999) Cellular survival: A play in three Akts Genes Dev, 13, pp. 2905-2927.
9. Dubs-Poterszman, MC and Tocque, B and Wasylyk, B. (1995) MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest Oncogene, 11, pp. 2445-2449.
10. Fakharzadeh, SS. and Trusko, SP. and George, DL. 1991 Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line EMBO J, 10, pp. 1565-1569.
11. Fambrough, D and McClure, K and Kazlauskas, A and Lander, ES. (1999) Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes Cell, 97, pp. 727-741.
12. Feng, J and Tamaskovic, R and Yang, Z and Brazil, DP and Merlo, A and Hess, D and Hemmings, BA. (2004) Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation J Biol Chem, 279, pp. 35510-35517.
13. Ganguli, G and Wasylyk, B. (2003) p53-independent functions of MDM2 Mol Cancer Res, 1, pp. 1027-1035.
14. Gaughan, L and Logan, IR and Neal, DE and Robson, CN. (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation Nucleic Acids Res, 33, pp. 13-26.
15. Ginsberg, D. (2002) E2F1 pathways to apoptosis FEBS Lett, 529, pp. 122-125.
16. Go, ML and Wu, X and Liu, XL. (2005) Chalcones: An update on cytotoxic and chemoprotective properties Curr Med Chem, 12, pp. 481-499.
17. Goetz, AW and van der Kuip, H and Maya, R and Oren, M and Aulitzky, WE. (2001) Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells Cancer Res, 61, pp. 7635-7641.
18. Goldberg, Z and Levav, Y and Krichevsky, S and Fibach, E and Haupt, Y. (2004) Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage Cell Cycle, 3, pp. 1188-1195.
19. Gottlieb, TM and Leal, JF and Seger, R and Taya, Y and Oren, M. (2002) Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis Oncogene, 21, pp. 1299-1303.
20. Gu, H and Neel, BG. (2003) The "Gab" in signal transduction Trends Cell Biol, 13, pp. 122-130.
21. Gudas, JM and Nguyen, H and Klein, RC and Katayose, D and Seth, P and Cowan, KH. (1995) Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells Clin Cancer Res, 1, pp. 71-80.
22. Hallstrom, TC and Nevins, JR. (2003) Specificity in the activation and control of transcription factor E2F-dependent apoptosis Proc Natl Acad Sci USA, 100, pp. 10848-10853.
23. Harris, L.C. (2005) MDM2 splice variants and their therapeutic implications Curr Cancer Drug Targets, 5, pp. 21-26.
24. Haupt, S and Haupt, Y. (2004) Manipulation of the tumor suppressor p53 for potentiating cancer therapy Semin Cancer Biol, 14, pp. 244-252.
25. Hazzalin, CA and Le Panse, R and Cano, E and Mahadevan, LC. (1998) Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction Mol Cell Biol, 18, pp. 1844-1854.
26. Hori, M and Shimazaki, J and Inagawa, S and Itabashi, M and Hori, M. (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer Breast Cancer Res Treat, 71, pp. 77-83.
27. Hsieh, JK and Chan, FS and O'Connor, DJ and Mittnacht, S and Zhong, S and Lu, X (1999) RB regulates the stability and the apoptotic function of p53 via MDM2 Mol Cell, 3, pp. 181-193.
28. Ittmann, M and Wieczorek, R and Heller, P and Dave, A and Provet, J and Krolewski, J. (1994) Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas Am J Pathol, 145, pp. 287-293.
29. Iwakuma, T and Lozano, G. (2003) MDM2, an introduction Mol Cancer Res, 1, pp. 993-1000.
30. Kadakia, M and Brown, TL and McGorry, MM and Berberich, SJ (2002) MdmX inhibits Smad transactivation Oncogene, 21, pp. 8776-8785.
31. Kinyamu, HK and Archer, TK (2003) Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol Cell Biol, 23, pp. 5867-5881.
32. Kussie, PH and Gorina, S and Marechal, V and Elenbaas, B and Moreau, J and Levine, AJ and Pavletich, NP. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science, 274, pp. 948-953.
33. Landers, JE and Haines, DS and Strauss, JF, 3rd and George, DL. (1994) Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells Oncogene, 9, pp. 2745-2750.
34. Leri, A and Liu, Y and Claudio, PP and Kajstura, J and Wang, X and Wang, S and Kang, P and Malhotra, A and Anversa, P. (1999) Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis Am J Pathol, 154, pp. 567-580.
35. Levav-Cohen, Y and Goldberg, Z and Zuckerman, V and Grossman, T and Haupt, S and Haupt, Y.C-Abl ad a modulator of p53 Biochem Biophys Res Commun. (In press)
36. Leveillard, T and Wasylyk, B. (1997) The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter J Biol Chem, 272, pp. 30651-30661.
37. Li, M and Brooks, CL and Wu-Baer, F and Chen, D and Baer, R and Gu, W. (2003) Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2 Science, 302, pp. 1972-1975.
38. Lin, HK and Wang, L and Hu, YC and Altuwaijri, S and Chang, C. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase EMBO J, 21, pp. 4037-4048.
39. Liu, G and Schwartz, JA and Brooks, SC. (1999) p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE Biochem Biophys Res Commun, 264, pp. 359-364.
40. Liu, G and Schwartz, JA and Brooks, SC. (2000) Estrogen receptor protects p53 from deactivation by human double minute-2 Cancer Res, 60, pp. 1810-1814.
41. Loughran, O and La Thangue, NB. (2000) Apoptotic and growth-promoting activity of E2F modulated by MDM2 Mol Cell Biol, 20, pp. 2186-2197.
42. Marine, JC and Jochemsen, AG. (2004) Mdmx and Mdm2: Brothers in arms? Cell Cycle, 3, pp. 900-904.
43. Martin, K and Trouche, D and Hagemeier, C and Sorensen, TS and La Thangue, NB and Kouzarides, T. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein Nature, 375, pp. 691-694.
44. Mayo, LD and Donner, DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus Proc Natl Acad Sci USA, 98, pp. 11598-11603.
45. Mayo, LD and Donner, DB (2002) The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network Trends Biochem Sci, 27, pp. 462-467.
46. McCann, AH and Kirley, A and Carney, DN and Corbally, N and Magee, HM and Keating, G and Dervan, PA. (1995) Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status Br J Cancer, 71, pp. 981-985.
47. Meek, DW and Knippschild, U. (2003) Posttranslational modification of MDM2 Mol Cancer Res, 1, pp. 1017-1026.
48. Metivier, R and Penot, G and Carmouche, RP and Hubner, MR and Reid, G and Denger, S and Manu, D and Brand, H and Kos, M and Benes, V and (2004) Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes EMBO J, 23, pp. 3653-3666.
49. Michael, D and Oren, M. (2003) The p53-Mdm2 module and the ubiquitin system Semin Cancer Biol, 13, pp. 49-58.
50. Milne, D and Kampanis, P and Nicol, S and Dias, S and Campbell, DG and Fuller-Pace, F and Meek, D (2004) A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein FEBS Lett, 577, pp. 270-276.
51. Minsky, N and Oren, M. (2004) The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression Mol Cell, 16, pp. 631-639.
52. Momand, J and Jung, D and Wilczynski, S and Niland, J. (1998) The MDM2 gene amplification database Nucleic Acids Res, 26, pp. 3453-3459.
53. Momand, J and Wu, HH and Dasgupta, G. (2000) MDM2 - master regulator of the p53 tumor suppressor protein Gene, 242, pp. 15-29.
54. Momand, J and Zambetti, GP and Olson, DC and George, D and Levine, AJ. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell, 69, pp. 1237-1245.
55. Ogawara, Y and Kishishita, S and Obata, T and Isazawa, Y and Suzuki, T and Tanaka, K and Masuyama, N and Gotoh, Y. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53 J Biol Chem, 277, pp. 21843-21850.
56. Okamoto, K and Kamibayashi, C and Serrano, M and Prives, C and Mumby, MC and Beach, D. (1996) p53-dependent association between cyclin G and the B′ subunit of protein phosphatase 2A Mol Cell Biol, 16, pp. 6593-6602.
57. Okamoto, K and Li, H and Jensen, MR and Zhang, T and Taya, Y and Thorgeirsson, SS and Prives, C. (2002) Cyclin G recruits PP2A to dephosphorylate Mdm2 Mol Cell, 9, pp. 761-771.
58. Oliner, JD and Kinzler, KW and Meltzer, PS and George, DL and Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas Nature, 358, pp. 80-83.
59. Oliner, JD and Pietenpol, JA and Thiagalingam, S and Gyuris, J and Kinzler, KW and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature, 362, pp. 857-860.
60. Onel, K and Cordon-Cardo, C. (2004) MDM2 and prognosis Mol Cancer Res, 2, pp. 1-8.
61. Polsky, D and Melzer, K and Hazan, C and Panageas, KS and Busam, K and Drobnjak, M and Kamino, H and Spira, JG and Kopf, AW and Houghton, A and (2002) HDM2 protein overexpression and prognosis in primary malignant melanoma J Natl Cancer Inst, 94, pp. 1803-1806.
62. Prasad, G and Wang, H and Agrawal, S and Zhang, R. (2002) Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme Anticancer Res, 22, pp. 107-116.
63. Quesnel, B and Preudhomme, C and Fournier, J and Fenaux, P and Peyrat, JP. (1994) MDM2 gene amplification in human breast cancer Eur J Cancer, 30A, pp. 982-984.
64. Reid, G and Hubner, MR and Metivier, R and Brand, H and Denger, S and Manu, D and Beaudouin, J and Ellenberg, J and Gannon, F. (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling Mol Cell, 11, pp. 695-707.
65. Ren, B and Cam, H and Takahashi, Y and Volkert, T and Terragni, J and Young, RA and Dynlacht, BD. (2002) E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints Genes Dev, 16, pp. 245-256.
66. Ries, S and Biederer, C and Woods, D and Shifman, O and Shirasawa, S and Sasazuki, T and McMahon, M and Oren, M and McCormick, F. (2000) Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF Cell, 103, pp. 321-330.
67. Saji, S and Okumura, N and Eguchi, H and Nakashima, S and Suzuki, A and Toi, M and Nozawa, Y and Saji, S and Hayashi, S. (2001) MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells Biochem Biophys Res Commun, 281, pp. 259-265.
68. Sengupta, S and Wasylyk, B. (2001) Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2 Genes Dev, 15, pp. 2367-2380.
69. Sengupta, S and Wasylyk, B. (2004) Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors Ann NY Acad Sci, 1024, pp. 54-71.
70. Shaulian, E and Resnitzky, D and Shifman, O and Blandino, G and Amsterdam, A and Yayon, A and Oren, M. (1997) Induction of Mdm2 and enhancement of cell survival by bFGF Oncogene, 15, pp. 2717-2725.
71. Shiraishi, T and Nielsen, PE. (2004) Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates Nucleic Acids Res, 32, pp. 4893-4902.
72. Stoll, R and Renner, C and Hansen, S and Palme, S and Klein, C and Belling, A and Zeslawski, W and Kamionka, M and Rehm, T and Muhlhahn, P and (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 Biochemistry, 40, pp. 336-344.
73. Sun, P and Dong, P and Dai, K and Hannon, GJ and Beach, D. (1998) p53-independent role of MDM2 in TGF-beta1 resistance Science, 282, pp. 2270-2272.
74. Thut, CJ and Goodrich, JA and Tjian, R. (1997) Repression of p53-mediated transcription by MDM2: A dual mechanism Genes Dev, 11, pp. 1974-1986.
75. Trotta, R and Vignudelli, T and Candini, O and Intine, RV and Pecorari, L and Guerzoni, C and Santilli, G and Byrom, MW and Goldoni, S and Ford, LP and (2003) BCR/ABL activates mdm2 mRNA translation via the La antigen Cancer Cell, 3, pp. 145-160.
76. Uchida, C and Miwa, S and Kitagawa, K and Hattori, T and Isobe, T and Otani, S and Oda, T and Sugimura, H and Kamijo, T and Ookawa, K and (2005) Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation EMBO J, 24, pp. 160-169.
77. Vassilev, LT and Vu, BT and Graves, B and Carvajal, D and Podlaski, F and Filipovic, Z and Kong, N and Kammlott, U and Lukacs, C and Klein, C and (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science, 303, pp. 844-848.
78. Wakefield, LM and Roberts, AB. (2002) TGF-beta signaling: Positive and negative effects on tumorigenesis Curr Opin Genet Dev, 12, pp. 22-29.
79. Wang, H and Nan, L and Yu, D and Agrawal, S and Zhang, R. (2001) Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms Clin Cancer Res, 7, pp. 3613-3624.
80. Wang, H and Nan, L and Yu, D and Lindsey, JR and Agrawal, S and Zhang, R. (2002) Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms Mol Med, 8, pp. 185-199.
81. Wang, H and Yu, D and Agrawal, S and Zhang, R. (2003) Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms Prostate, 54, pp. 194-205.
82. Watanabe, T and Hotta, T and Ichikawa, A and Kinoshita, T and Nagai, H and Uchida, T and Murate, T and Saito, H. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin Blood, 84, pp. 3158-3165.
83. Weber, HO and Ludwig, RL and Morrison, D and Kotlyarov, A and Gaestel, M and Vousden, KH. (2005) HDM2 phosphorylation by MAPKAP kinase 2 Oncogene, 24, pp. 1965-1972.
84. Wu, G.S. (2004) The functional interactions between the p53 and MAPK signaling pathways Cancer Biol Ther, 3, pp. 156-161.
85. Yam, CH and Siu, WY and Arooz, T and Chiu, CH and Lau, A and Wang, XQ and Poon, RY. (1999) MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins Cancer Res, 59, pp. 5075-5078.
86. Zhang, R and Wang, H and Agrawal, S. (2005) Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and in vivo activities, and mechanisms Curr Cancer Drug Targets, 5, pp. 43-49.
87. Zhang, Z and Wang, H and Prasad, G and Li, M and Yu, D and Bonner, JA and Agrawal, S and Zhang, R. (2004) Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models Clin Cancer Res, 10, pp. 1263-1273.
88. Zhao, J and Wang, M and Chen, J and Luo, A and Wang, X and Wu, M and Yin, D and Liu, Z. (2002) The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure Cancer Lett, 183, pp. 69-77.
89. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3:973-982